EHA 2017 | Can we target AML with CAR T-cells?
Attilio Bondanza
• 27 Jun 2017
CAR T-cells are the most exciting type of therapy in the hematology world. They have been used in a variety of diseases and demonstrated to have deep responses, lasting up to 1 year. The most common targets are CD19 and BCMA; however, acute myeloid leukemia (AML) cells do not express these targets, which difficults the use of existing CAR T-cells constructs. Here, Attilio Bondanza, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy talks about the work himself and his colleagues have been doing on CAR T-cells that target CD44 isoform variant 6 (CD44v6), which is over-expressed in AML, and that was presented at the European Hematology Association (EHA) 2017 meeting.
